Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The Company’s pipeline focuses in three strategic therapeutic areas (STArs): genetic medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; cardio-metabolic disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, and hepatic infectious disease, with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), ALN-AT3, ALN-CC5, ALN-AS1, ALN-AAT, ALN-GO1, ALN-TMP, ALN-PCS, ALN-PCSsc, ALN-AC3, ALN-ANG, ANGPTL3, ALN-HBV, ALN-HDV and ALN-PDL. It is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.

Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2002
Size (employees)
514 (est)
Alnylam Pharmaceuticals was founded in 2002 and is headquartered in Cambridge, US

Key People at Alnylam Pharmaceuticals

Saraswathy (Sara) Nochur

Saraswathy (Sara) Nochur

Senior Vice President, Regulatory Affairs & Quality Assurance
Muthiah (Mano) Manoharan

Muthiah (Mano) Manoharan

Senior Vice President, Drug Discovery
Lubomir (Lubo) Nechev

Lubomir (Lubo) Nechev

Vice President, Process Sciences
Mary Beth DeLena

Mary Beth DeLena

VP, Legal
David Bartel

David Bartel

Scientific Advisory Board and Founder

Alnylam Pharmaceuticals Office Locations

Alnylam Pharmaceuticals has offices in Cambridge, Windsor and Maidenhead and Zug
Cambridge, US (HQ)
300 Third St
Zug, CH
19 Dammstrasse
Windsor and Maidenhead, GB
Braywick Rd

Alnylam Pharmaceuticals Data and Metrics

Alnylam Pharmaceuticals Financial Metrics

USD

Net income (Q1, 2017)

(107.3 m)

EBIT (Q1, 2017)

(106.5 m)

Market capitalization (17-Aug-2017)

7.1 b

Cash (31-Mar-2017)

171.1 m
Alnylam Pharmaceuticals's current market capitalization is $7.1 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

R&D expense

382.4 b

General and administrative expense

89.4 b

Operating expense total

140.1 m455.5 m337.1 m471.7 b

EBIT

(92.9 m)(405 m)(296 m)(424.6 b)

Interest income

8.3 b

Pre tax profit

(410.1 b)

Net Income

(89.2 m)(360.4 m)(290.1 m)(410.1 b)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

44.7 m46.3 m58 m67 m68.6 m96.3 m83.2 m97.9 m87 m

General and administrative expense

11.5 m9.9 m12.7 m14.6 m16 m21.1 m18 m22.4 m38.5 m

Operating expense total

56.2 m56.2 m70.8 m81.6 m84.7 m117.4 m101.2 m120.3 m125.5 m

EBIT

(45 m)(45.2 m)(52.2 m)(72.9 m)(78.3 m)(110 m)(92.5 m)(106.7 m)(106.5 m)

Interest income

693 k753 k1 m1.6 m1.6 m1.8 m2.1 m2.2 m2.1 m

Pre tax profit

(44.4 m)(43.9 m)(51.2 m)(71.4 m)(76.8 m)(103 m)(90.1 m)

Income tax expense

(431 k)

Net Income

(44.1 m)(44 m)(50.8 m)(71.8 m)(76.8 m)(103 m)(90.1 m)(104.1 m)(107.3 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

53.2 m75.2 m180.9 m193.6 m

Accounts Receivable

17.9 m

Inventories

3.9 m9.7 m16.6 m21.7 m

Current Assets

254 m746.4 m1.1 b671.9 m

PP&E

16.4 m21.7 m27.8 m114.6 m

Total Assets

420.5 m1.1 b1.4 b1.3 b

Accounts Payable

5.9 m15.1 m16.8 m54.5 m

Total Debt

150 m

Current Liabilities

53.9 m95.3 m62.1 m131.7 m

Total Liabilities

342.6 m

Additional Paid-in Capital

846.2 m1.8 b2.5 b2.6 b

Retained Earnings

(596.2 m)(956.6 m)(1.2 b)(1.7 b)

Total Equity

270.3 m936.3 m1.3 b920.2 m

Debt to Equity Ratio

0.2 x

Debt to Assets Ratio

0.1 x

Financial Leverage

1.6 x1.2 x1.1 x1.4 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

80.7 m82.7 m306.6 m151.3 m149.2 m231.3 m271.1 m168.5 m171.1 m

Current Assets

665.1 m643 m1.1 b1 b1 b1.1 b888.1 m747.6 m597.2 m

PP&E

17 m18.8 m21.2 m25.2 m26.3 m36.8 m55.4 m74.2 m130 m

Total Assets

1 b986.4 m1.6 b1.5 b1.4 b1.3 b1.4 b1.3 b1.1 b

Accounts Payable

6.2 m5.2 m15.5 m15.7 m14.3 m17.4 m12.8 m23.1 m25.4 m

Current Liabilities

53.7 m56.8 m80.7 m66.6 m57.1 m66.4 m70.6 m81.8 m95.8 m

Additional Paid-in Capital

1.8 b1.8 b2.5 b2.5 b2.5 b2.5 b2.6 b2.6 b2.6 b

Retained Earnings

(891.3 m)(935.2 m)(1 b)(1.1 b)(1.2 b)(1.3 b)(1.4 b)(1.5 b)(1.8 b)

Total Equity

942.3 m904.5 m1.5 b1.4 b1.3 b1.2 b1.1 b1 b830.9 m

Financial Leverage

1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.3 x1.3 x1.4 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(89.2 m)(360.4 m)(290.1 m)(410.1 m)

Depreciation and Amortization

10.2 m11.9 m19.1 m15.1 m

Accounts Payable

1.8 m8.8 m1.7 m10.1 m

Cash From Operating Activities

(68.7 m)(165.6 m)(189.1 m)(307.7 m)

Purchases of PP&E

(4 m)(9 m)(13 m)(64.6 m)

Cash From Investing Activities

(130.5 m)(548.8 m)(321.3 m)142.6 m

Cash From Financing Activities

200.9 m736.5 m616.2 m177.8 m

Interest Paid

1.1 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(44.1 m)(44 m)(50.8 m)(71.8 m)(76.8 m)(103 m)(90.1 m)(104.1 m)(107.3 m)

Accounts Payable

6.2 m5.2 m15.5 m15.7 m14.3 m17.4 m12.8 m23.1 m25.4 m
Y, 2017

Financial Leverage

1.4 x

Alnylam Pharmaceuticals Market Value History

Alnylam Pharmaceuticals Median Salaries

Source: 19 public H-1B filings from Alnylam Pharmaceuticals

Traffic Overview of Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Online and Social Media Presence

Alnylam Pharmaceuticals Company Life and Culture

You may also be interested in